Brief: Kane Biotech Successfully Completes Safety And Biocompatibility Studies For Dispersinb Wound Gel
22/03/2022 12:25
March 22 (Reuters) - Kane Biotech Inc KNE.V :
* KANE BIOTECH SUCCESSFULLY COMPLETES SAFETY AND
BIOCOMPATIBILITY
STUDIES FOR DISPERSINB® WOUND GEL IN PREPARATION FOR HUMAN
CLINICAL TRIALS
* KANE BIOTECH INC - STUDIES AND UPCOMING CLINICAL TRIAL ARE
FUNDED BY $2.7 MILLION USD GRANT FROM UNITED STATES DOD THROUGH
MTEC
Source text for Eikon: ID:nGNX5TQTT6
Further company coverage: KNE.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kane Biotech
See all newsBrief: Kane Biotech Announces FDA 510(K) Clearance For Revyve® Antimicrobial Skin And Wound Cleanser
Brief: Kane Biotech Restarts Commercial Activities And Strengthens North American Management
Brief: Kane Biotech Completes U.S. FDA 510(K) Submission For Revyve Antimicrobial Wound Cleanser
Brief: Kane Biotech Announces Second Quarter 2025 Financial Results
Brief: Kane Biotech provides further corporate update